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Abstract
The emphasis of treatment in Crohn’s disease has evolved from a reactive model to “treat-to-target” approaches. Cross-sec-
tional imaging has rapidly evolved in parallel, with a growing evidence base supporting its abilities for diagnosis, monitoring 
and prognostication. Whilst there are differences in emphasis between Europe and North America, particularly around the 
type of imaging modalities and patterns of multidisciplinary care, there is increasing convergence. This perspective piece 
provides an overview of the evolving role of cross-sectional imaging in Crohn’s disease, discusses practice differences 
between North America and Europe and provides suggestions on areas for future collaboration and research priorities.
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Introduction
Management of Crohn’s disease has traditionally been reac-
tive and based around controlling patient symptoms, with 
stepwise escalation of therapy over time. In recent years, 
however, the emphasis of treatment has switched to early 
aggressive control of inflammation, with the goal of achiev-
ing mucosal healing and reducing long-term bowel damage. 
For example, in the REACT trial, early combined immu-
nosuppression reduced major adverse events such as sur-
gery and hospitalization compared to conventional therapy 
[1]. This change in paradigm has occurred in parallel with 
rapid developments in cross-sectional imaging, resulting in 
unprecedented opportunities for radiologists to contribute to 
the care of patients with Crohn’s disease. Radiological imag-
ing has evolved from simply aiding diagnosis and detect-
ing complications to playing a central role in quantifying 
inflammatory activity, monitoring treatment response and 
potentially facilitating prognostication. Several important 
publications in 2018 reflect this expanding role, including 
the METRIC trial [2], Society of Abdominal Radiology 
(SAR) Crohn’s disease-focused panel consensus guidelines 
on the utilization of CT and MRI in Crohn’s disease [3], 
and the joint European Crohn’s and Colitis Organization 
(ECCO), European Society of Gastrointestinal and Abdomi-
nal Radiology (ESGAR) consensus guidelines on diagnostic 
assessment in inflammatory bowel disease [4, 5]. Whilst the 
direction of travel is very similar between the radiological 
communities in North America and Europe, there remain 
practice differences. These must be recognized so that efforts 
to unify approaches either side of the Atlantic can be made 
where appropriate to fully realize the potential of cross-sec-
tional imaging. This perspective piece provides an overview 
of the evolving role of cross-sectional imaging in Crohn’s 
disease, discusses practice differences between North Amer-
ica and Europe and provides suggestions on areas for future 
collaboration and research priorities.
Modalities used in Crohn’s disease imaging
Europe
In Europe, there is increased emphasis on MR enteography 
(MRE) and ultrasound (US) over CT enterography (CTE) 
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for imaging Crohn’s disease. This mainly stems from fears 
about cumulative radiation exposure in this often young 
patient cohort who frequently undergo repeat imaging over 
the course of their disease, but may also be influenced by 
reimbursement patterns in individual healthcare systems. 
This influences both the research and clinical communi-
ties. For example, the English National Institute of Health 
Research commissioned the METRIC trial, whose remit was 
specifically to compare diagnostic accuracy of MRE and 
US (rather than CTE) [2]. Consensus guidelines also reflect 
this approach; the ECCO-ESGAR consensus guidelines 
on diagnostic assessment in inflammatory bowel disease 
states “Radiation exposure is a limitation of CT and should 
only be used if MRI or ultrasound is not available”. Small 
bowel imaging is mandated at diagnosis and cross-sectional 
imaging (using MRE or US) is already considered a robust 
alternative to ileocolonoscopy (IC) in treatment monitoring 
[5]. In the UK, annual assessment of patients on biologi-
cal therapy is mandated by the National Institute for Health 
and Care Excellence (NICE), and increasingly MRE or US 
form part of this assessment. Although the METRIC trial 
showed that in a national health service setting MRE is more 
accurate than US for diagnosing and staging small bowel 
Crohn’s disease [2], US itself performed well and has many 
advocates. For example, US has a high sensitivity for small 
bowel disease and is often used to investigate patients with 
nonspecific abdominal symptoms, usually in conjunction 
with biochemical markers such as calprotectin. It also is 
widely used in treatment follow-up. Physicians performing 
US examinations is gaining acceptance, driven by acute care 
and emergency medicine [6]. In continental Europe, gastro-
enterologists (as opposed to radiologists) commonly perform 
small bowel US; US technology is easily accessible with 
hand-held bedside devices increasingly available [7]. The 
ECCO, for example, is very active in prompting US training 
and education amongst gastroenterologists. In some coun-
tries, such as Germany, abdominal US is part of the training 
program for gastroenterologists, and US performed by non-
radiologists may achieve acceptable diagnostic accuracy [8]. 
Furthermore, the ability of the gastroenterologist to interpret 
the findings real time within the clinical context may be 
advantageous [9], and such interactions could strengthen 
the physician–patient relationship [8]. CTE is of course 
undoubtedly used in Europe particularly in older patients 
and in some centers in patients with nonspecific abdominal 
symptoms in whom enteropathy is being excluded. However, 
if available, MRE and US are recommended as first line in 
the Crohn’s disease population.
North America
There has been a rapid growth in the use of CT and MR 
enterography throughout the United States in the last two 
decades, and these tests are now widely available. Compared 
to Europe, practice pressures within most United States 
have precluded routine use of specialized bowel ultrasound, 
which requires dedicated individuals with clear expertise. 
Additionally, while MR enterography is generally preferred 
for pediatric and younger patients, and patients undergo-
ing imaging to determine response to therapy [10], there is 
increased utilization of CT enterography for the imaging of 
small bowel diseases for several reasons, despite the require-
ment for low-dose radiation at CT. First, CT is ubiquitous 
and widely available and accessible in most emergency 
rooms and outpatient radiology practices, it is quick and 
the performance of CT and MR enterography are felt to be 
identical for the detection and staging of active inflamma-
tory Crohn’s disease [11]. As cross-sectional enterography is 
used for an expanding list of indications, the MR scanners in 
many radiology practices cannot accommodate small bowel 
imaging in a timely fashion, so patients with diarrhea (poten-
tially due to pancreatic disease, or with IBS symptoms) or 
with other suspected indications (e.g., NSAID enteropa-
thy) are imaged with CT enterography. Low-dose CT tech-
niques such as iterative reconstruction and kV selection are 
now widely available, and United States radiologists have 
become more accustomed to interpreting noisier, lower dose 
images such as their European colleagues, so CT imaging 
can be performed in most practices at doses that are similar 
to annual background doses [12, 13]. Moreover, multiple 
studies have demonstrated the benefit of CT in detecting 
unanticipated complications in both the emergency room 
and outpatient setting [14–16].The United States has a larger 
number of new Crohn’s disease diagnosed at age 60 years or 
older, in addition to those being treated for existing Crohn’s 
disease [17]. While these older patients tend to have less 
aggressive disease, they have worse outcomes [17–19], and 
CT enterography is often a more attractive alternative in 
elderly patients owing to the speed of acquisition, its ability 
to identify other pathologies, and the decreased perceived 
risk of low-dose radiation. For all these reasons, many gas-
troenterologists now involve their Crohn’s disease patients 
in the selection of cross-sectional bowel imaging tests, and 
refer many patients with non-Crohn’s alternatives for initial 
CT imaging.
National and international oversight
Europe
Multidisciplinary management of Crohn’s disease is well 
established in Europe and regular face to face multidiscipli-
nary team meetings including gastroenterologists, radiolo-
gists, surgeons, and nurses are often mandated for hospitals 
running inflammatory bowel disease services, a concept long 
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implemented in the UK for example [20]. Indeed, manage-
ment of complex Crohn’s disease is on a par with cancer 
management, and team approach is deemed essential. The 
multidisciplinary nature of managing Crohn’s disease is 
reflected by the established international joint consensus 
guidelines published by ECCO and ESGAR, originally in 
2013 [21] and recently updated [4, 5]. National guidelines 
are also truly multidisciplinary, for example those devel-
oped the British Society of Gastroenterology in the UK. 
Such consensus documents repeatedly emphasize the com-
plementarity of cross-sectional imaging and IC alongside 
biochemical markers such as CRP and calprotectin in all 
aspects of Crohn’s disease management. This is exemplified 
by many statements in 2018 ECCO/ESGAR guidelines, for 
example “Endoscopic or cross-sectional reassessment in CD 
should be considered in cases of relapse, persistent disease 
activity, new unexplained symptoms, and before switch of 
therapy” [5], and “Magnetic resonance [MR] enterography-
based indexes have high accuracy for assessing luminal 
CD activity and can be used in clinical trials for measuring 
activity and response to pharmacological interventions” [4]. 
Multidisciplinary conferences such as the United European 
Gastroenterology week have long-hosted educational ses-
sions with gastroenterological and radiological speakers, 
reflecting this multidisciplinary approach.
North America
In the United States, outside of major academic centers, 
radiologists, gastroenterologists, and colorectal surgeons 
have traditionally tended to attend their individual subspe-
cialty medical meetings. With the formation of the Society 
of Abdominal Radiology (SAR), Crohn’s disease-focused 
panel, which includes non-radiology gastroenterologist 
IBD experts as well as pediatric, European and Asian radi-
ologists, there has been increasing collaboration with the 
American Gastroenterology Association (AGA) imaging and 
advanced technology (IAT) and inflammatory bowel disease 
(IBD) sections, as well as the Society of Pediatric Radiology 
(SPR). After the creation of technical specifications for MR 
and CT enterography [22, 23], the SAR Crohn’s disease-
focused panel worked with AGA-IAT, AGA-IBD, and SPR 
members to develop the aforementioned consensus recom-
mendations for the utilization and interpretation of cross-
sectional enterography in small bowel Crohn’s disease [3]. 
Concurrent with this process has been the increasing realiza-
tion in the need for and complementarity of cross-sectional 
enterography in identifying substantial small bowel inflam-
mation in both adult and pediatric Crohn’s patients that is not 
identified by ileocolonoscopy alone [24, 25], and that cross-
sectional and optical imaging are complementary rather than 
competing techniques: cross-sectional enterography cannot 
visualize the mucosa (or mucosal healing) or perform cancer 
surveillance or biopsies, and many features of Crohn’s dis-
ease (e.g., colorectal strictures, stricturing of the ileocecal 
valve, skipping of the terminal ileum) hamper endoscopic 
diagnosis. Additionally, there is increasing understanding 
of how serum markers such as CRP and fecal markers such 
as calprotectin can be used to guide management decisions 
in conjunction with cross-sectional imaging [26, 27]. These 
parallel developments have led to an increasing number of 
interdisciplinary inflammatory bowel disease conferences 
within institutions patterned after multidisciplinary tumor 
boards, as well as increasing interdisciplinary session at 
major gastroenterology meetings in IBD such as the com-
bined meeting of the Crohn’s and Colitis Congress sup-
ported by the Crohn’s and Colitis Foundation and the AGA 
IBD section [28]. There is also increasing focus on the use 
of imaging endpoints in therapeutic studies and their joint 
development by gastroenterologists and radiologists [29].
Treatment strategy and evolving role 
of imaging
As can be seen from the above discussion, although differ-
ences exist between Europe and North America, there is 
increasing convergence in recommendations from multidis-
ciplinary bodies. The SAR/SPR/AGA consensus recommen-
dations indicate that MR and CT enterography be performed 
not only at diagnosis of small bowel Crohn’s disease, but 
considered in surveillance when assessing response to ther-
apy. Similar recommendations (for MRE and US) are also 
made by the joint ECCO/ESGAR consensus statements [4, 
5]. Mucosal healing at endoscopy is associated with longer 
periods of subsequent clinical remission [30]. Building upon 
the knowledge that mucosal healing is achieved in only a 
minority of patients, Colombel and colleagues recently dem-
onstrated in the CALM study that escalation of treatment 
based on objective markers of disease progression led to bet-
ter clinical and endoscopic outcomes [31]. This has impor-
tant implications for cross-sectional imaging given its ability 
to quantify disease burden and activity. Complete response 
to therapy as shown by resolution of all imaging findings 
of inflammation at US, CT and MR enterography is termed 
“transmural healing”, as these cross-sectional techniques 
image the bowel wall. Of note, abnormalities on cross-
sectional imaging, such as wall thickening, strictures and 
creeping fat, frequently persist, despite achieving endoscopic 
remission [32]. MR enterography has an approximately 90% 
accuracy for mucosal healing [33], and other studies have 
demonstrated improved outcomes or prediction of clinical 
remission with transmural healing [34, 35]. In contrast to 
transmural healing, response to therapy can also be seen 
with cross-sectional enterography [36, 37]. Deepak et al. 
have shown that response (defined by decrease in length or 
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severity of inflammation for all inflamed bowel segments) 
results in lower rates of hospitalization and surgery, and that 
maintaining patients in a state of response on imaging dra-
matically reduces the risk of small bowel surgery [38, 39].
Next steps (near future)
In recent years, the treat-to-target paradigm has gained 
significant traction in the care of Crohn’s disease patients 
[40]. This strategy involves setting of a specific goal, such 
as mucosal or transmural healing, that signals low or absent 
disease activity. This goal is then evaluated frequently to 
monitor progress and the treatment plan adjusted if the target 
is not achieved. Cross-sectional imaging may have a crucial 
role in this monitoring strategy as it is non-invasive with a 
lower complication rate then invasive colonoscopy, provid-
ing greater patient comfort and safety [41]. To achieve this, 
we must embed cross-sectional imaging into large clinical 
trials, so we can truly establish its added value, not only in 
monitoring disease response (for example as an endpoint in 
clinical trials of novel therapies), but also predicting longer 
term outcomes. Whilst the CALM study provides evidence 
that objective monitoring leads to better outcomes [31], it is 
unclear if imaging targets are superior to cheaper and sim-
ple biochemical markers. It is very possible that the goal of 
treatment will shift from mucosal to transmural healing, but 
such an evolution will require more compelling evidence, 
in particular on the natural history of Crohn’s disease. We 
imagine that the future will continue to bring consensus, 
refinement and reproducibility to cross-sectional imaging 
criteria for treatment response (regardless of the chosen 
modality), as well as developing algorithms to combine 
imaging with other biomarkers. Cross-sectional imaging 
holds many advantages over other monitoring techniques 
in several situations, such as isolated small bowel Crohn’s 
disease or perianal Crohn’s disease and is already forming 
an important part of assessment of new therapies such as 
janus kinase inhibitors (NCT03046056 and NCT03077412). 
Emphasis is currently increasingly placed on MRE, but we 
must not forget the undoubted strengths of US and CTE, 
both of which will play an important role in this evolution. 
Their exact place in the future management algorithms will 
need to be defined. Teaching the skills of enteric US and 
fully utilizing the dose reduction techniques available for CT 
should continue. Whilst it is essential to address technical 
questions, for example the added value of diffusion-weighted 
imaging and motility quantification as part of MRE, impor-
tantly this should not distract radiologists from collaborat-
ing externally. We must emerge from our radiological silos 
and develop (and if possible, combine) the existing inter-
national consensus groups involving radiological (such as 
SAR, ESGAR) and clinical societies (such as AGA, ECCO, 
and UEG). We must fully involve patients in our work-
patients are not only involved in their own care, but play 
an increasingly important role in setting the agenda of the 
major funding agencies and our imaging technologies must 
be developed with them. In parallel, we must reach out to 
other disciplines such as computationalists, physicists and 
mathematicians. Interdisciplinary groups are essential. For 
example, current MRI activity scores are too time consum-
ing and cumbersome for use in day to day clinical practice. 
However, radiomics or artificial intelligence techniques will 
likely make annotation of disease severity and length for 
inflamed bowel segments rapid, reproducible and available 
in the clinic. Indeed, some progress has already been made 
in automated measurement of bowel wall thickness and 
enhancement [42]. In the clinical care of our patients, we 
must embrace multidisciplinary team working; we anticipate 
that interdisciplinary inflammatory bowel disease boards 
will become the norm at individual institutions in North 
America, as well as Europe.
Future areas that will require interdisciplinary expertise, 
are the imaging of Crohn’s disease-associated strictures and 
fibrosis. This is perhaps one of the largest areas of unmet 
need in Crohn’s disease, and research is urgently needed 
given the absence of validated definitions or response param-
eters. Based on prior experience, this area is now being 
jointly and systematically developed by gastroenterologists, 
radiologists and clinical trialists to standardize definitions, 
diagnosis and treatment targets for stricturing Crohn’s dis-
ease [43]. In parallel, several novel imaging techniques are 
being developed to differentiate inflammation from fibrosis, 
a critical step towards future anti-fibrotic therapies [44].
Summary
In the recent years, the emphasis of treatment in Crohn’s dis-
ease has evolved from a reactive model to “treat-to-target” 
approaches. Cross-sectional imaging has rapidly evolved in 
parallel, with a growing evidence base supporting its abili-
ties for diagnosis, monitoring and prognostication. Whilst 
there are differences in emphasis between Europe and North 
America, particularly around the type of imaging modalities 
and patterns of multidisciplinary care, there is increasing 
convergence. This is exemplified by multidisciplinary con-
sensus statements which have emerged on either side of the 
Atlantic in 2018. Although it seems likely US will remain 
primarily practiced in Europe, there is clear commonality 
in approaches to MRE, as well as CTE. This is a time of 
unparalleled opportunity for radiologists to meaningfully 
impact on the care of Crohn’s disease long into the future. 
By engaging widely, both with each other, and with other 
disciplines, we will be able to realize the potential of cross-
sectional imaging in the management of Crohn’s disease.
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